L8S Stock Chart & Stats
€2.78
€0.00(0.00%)
At close: 4:00 PM EDT
€2.78
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.78 - €2.78
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€39.59M
Enterprise Value€25.45
Total Cash (Recent Filing)€13.76M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 16, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding21,035,930
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-8.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.45Price Target Upside24.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA debt-free balance sheet limits interest obligations and reduces refinancing pressure while the company advances its pipeline. This provides greater flexibility to direct available capital toward development, manufacturing, and regulatory work.
Extended Cash RunwayThe financing materially extends operational runway and supports manufacturing and regulatory activities for GTx-104. Longer funding visibility can reduce near-term program disruption and provide time to address approval requirements.
Clinical And Product DifferentiationRegulatory feedback focused on manufacturing and non-clinical requirements rather than clinical shortcomings. Favorable trial outcomes, orphan drug status, and potential intellectual property protection could support a differentiated position if approval is achieved.
Bears Say
No Commercial RevenueThe absence of revenue confirms that GRCE remains pre-commercial and dependent on successful development and approval of its pipeline. Material recurring losses leave no operating proof of demand, pricing power, or commercial profitability.
Persistent Cash BurnSustained cash burn means the business cannot currently fund operations internally and must rely on capital markets or other financing. Continued funding needs may dilute shareholders and constrain investment if financing conditions weaken.
Manufacturing And Regulatory Execution RiskGTx-104 resubmission depends on resolving facility compliance, technology-transfer, leachables, and toxicology requirements. Delays or failures in establishing a compliant manufacturing pathway could postpone approval and extend the pre-revenue period.
Grace Therapeutics News
L8S FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was €2.78 and its highest was €2.78 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is €39.59M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 87 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.786 earnings per share for the quarter, missing the consensus estimate of -€0.111 by -€0.675.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Undervalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 21,035,930 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -€0.786 in its last earnings report, missing expectations of -€0.111. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in DE:L8S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grace Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€3.45 (24.27% Upside)
€3.45 (24.27% Upside)
Insider Transactions
Bought Shares
Worth €20.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.27%
Trailing 12-Months
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
L8S Stock 12 Month Forecast
Average Price Target
€3.45
▲(24.27% Upside)